BIOMAT Database Logo BIOMAT Database Logo

A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. 1990

S Makino, and K Sasaki, and T Nakayama, and S Oka, and T Urano, and M Kimura, and R Kawana, and A M Yamamura
Department of Virology, Kitasato Institute, Japan.

Trivalent virus vaccine, containing measles AIK-C strain, mumps Hoshino strain, and rubella Takahashi strain, was administered to a total of 1369 healthy children, 8 months to 18 years of age. For comparative study, monovalent vaccines of AIK-C strain and Hoshino strain were administered to 147 and 122 initially seronegative children, respectively. The clinical and serological responses following vaccination were analyzed. Among the recipients of the trivalent vaccine, 893 were initially seronegative to all three viruses. Inoculation induced sufficient serological responses: 99.7% for measles and rubella viruses and 96.3% for mumps virus. The incidence of febrile reaction (greater than or equal to 37.5 degrees C axillary temperature) was low, 15.9%, and a temperature of 39.0 degrees C or higher occurred in only 1.3% of the subjects. The seroconversion rate, magnitude of antibody titers, and incidence of clinical reactions following the trivalent vaccination were similar to those occurring after the monovalent measles vaccination.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008458 Measles Vaccine A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed) Vaccine, Measles
D009108 Mumps Vaccine Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine. Inactivated Mumps Vaccine,Inactivated Mumps Virus Vaccine,Live Attenuated Mumps Vaccine,Live Attenuated Mumps Virus Vaccine,Mumps Vaccine, Inactivated,Mumps Vaccine, Live Attenuated,Mumps Virus Vaccine, Inactivated,Mumps Virus Vaccine, Live Attenuated,Vaccine, Inactivated Mumps,Vaccine, Mumps
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody

Related Publications

S Makino, and K Sasaki, and T Nakayama, and S Oka, and T Urano, and M Kimura, and R Kawana, and A M Yamamura
Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies.
October 1971, JAMA,
S Makino, and K Sasaki, and T Nakayama, and S Oka, and T Urano, and M Kimura, and R Kawana, and A M Yamamura
Combined live rubella-mumps virus vaccine. Findings in clinical-laboratory studies.
May 1971, JAMA,
S Makino, and K Sasaki, and T Nakayama, and S Oka, and T Urano, and M Kimura, and R Kawana, and A M Yamamura
Combined live measles-rubella virus vaccine. Findings in clinical laboratory studies.
October 1971, The Journal of pediatrics,
S Makino, and K Sasaki, and T Nakayama, and S Oka, and T Urano, and M Kimura, and R Kawana, and A M Yamamura
Clinical evaluation of a new measles-mumps-rubella trivalent vaccine.
December 1975, American journal of diseases of children (1960),
S Makino, and K Sasaki, and T Nakayama, and S Oka, and T Urano, and M Kimura, and R Kawana, and A M Yamamura
Erythema multiforme following live attenuated trivalent measles-mumps-rubella vaccine.
January 2006, Acta dermato-venereologica,
S Makino, and K Sasaki, and T Nakayama, and S Oka, and T Urano, and M Kimura, and R Kawana, and A M Yamamura
Combined live measles, mumps, rubella vaccine. Immunological response.
May 1971, American journal of diseases of children (1960),
S Makino, and K Sasaki, and T Nakayama, and S Oka, and T Urano, and M Kimura, and R Kawana, and A M Yamamura
Effects and side effects of a new trivalent combined measles-mumps-rubella (MMR) vaccine.
September 1982, The Tokai journal of experimental and clinical medicine,
S Makino, and K Sasaki, and T Nakayama, and S Oka, and T Urano, and M Kimura, and R Kawana, and A M Yamamura
Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children.
September 1984, American journal of diseases of children (1960),
S Makino, and K Sasaki, and T Nakayama, and S Oka, and T Urano, and M Kimura, and R Kawana, and A M Yamamura
Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
January 2019, Human vaccines & immunotherapeutics,
S Makino, and K Sasaki, and T Nakayama, and S Oka, and T Urano, and M Kimura, and R Kawana, and A M Yamamura
Studies on live rubella vaccine. V. Quantitative aspects of interference between rubella, measles and mumps viruses in their trivalent vaccine.
December 1974, Biken journal,
Copied contents to your clipboard!